Sub: Transcript of the Earnings call conducted on May 10, 2023 Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations, 2015, please find enclosed the. | May 16, 2023
Operator: Ladies and gentlemen, good day, and welcome to the Dr. Reddy s Q4 FY 23 Earnings Conference Call. [Operator Instructions]. I now hand the conference over to Ms. Richa Periwal.
A new report from Motilal Oswal notes that increasingly Indian pharma companies are finding it hard to meet the compliance criteria set by USFDA, leading to regulatory hurdles for the US generics market.
With years of experience under his belt, Satyanarayana Chava is now successfully guiding his company Laurus Labs on the research path for a better tomorrow
Covid Third Wave: The evolving nature of the corona virus there is a need for new vaccines and therapeutics to halt the surge, which throws up a new business opportunity for the indian pharma industry. what is planned?